#	Pagina
attuale pagina	/open-h2020/projects/199732/index.html

Opendata, web and dolomites

HERCULES SIGNED

Comprehensive characterization and effective combinatorial targeting of high-grade serous ovarian cancer via single-cell analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

HERCULES project word cloud

Explore the words cloud of the HERCULES project. It provides you a very rough idea of what is the project "HERCULES" about.

move metastatic collected suggest fresh hgs clinically levels drug expensive longitudinally combinatorial regimen benefit ovarian predict error strategy vivo combinations trials data tools multiple anatomic clinical sites deaths prospectively cytometry fluorescence lasting single combination pharmaceutical comprehensively diagnostic health women disease patients predictive treatments activated models ovca sorting lack systematic serous hercules retrospective populations breakthrough suggestions kills industry multidisciplinary mass ex validated cell decrease kit cancer modalities paves commercialise prediction reduce patient stratified treatment innovative therapeutic network inefficient takes kill followed subpopulations specimens marked cohorts grade experiments translated characterise regimens medicine advantage tumors transcriptomics care trial right efforts toward individual genetic biomarker actionable prospective screening

Project "HERCULES" data sheet

The following table provides information about the project.

Coordinator	HELSINGIN YLIOPISTO Organization address address: YLIOPISTONKATU 3 city: HELSINGIN YLIOPISTO postcode: 14 website: www.helsinki.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Finland [FI]
Project website	http://project-hercules.eu/
Total cost	5˙994˙868 €
EC max contribution	5˙994˙868 € (100%)
Programme	1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
Code Call	H2020-PHC-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	HELSINGIN YLIOPISTO HELSINGIN YLIOPISTO Organization address address: YLIOPISTONKATU 3 city: HELSINGIN YLIOPISTO postcode: 14 website: www.helsinki.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (HELSINGIN YLIOPISTO)	coordinator	2˙444˙812.00
2	TURUN YLIOPISTO TURUN YLIOPISTO Organization address address: YLIOPISTONMAKI city: Turku postcode: 20014 website: www.utu.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (Turku)	participant	999˙211.00
3	THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE Organization address address: TRINITY LANE THE OLD SCHOOLS city: CAMBRIDGE postcode: CB2 1TN website: www.cam.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	participant	566˙969.00
4	INSTITUT PASTEUR INSTITUT PASTEUR Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 website: http://www.pasteur.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS CEDEX 15)	participant	360˙101.00
5	ISTITUTO SUPERIORE DI SANITA ISTITUTO SUPERIORE DI SANITA Organization address address: Viale Regina Elena 299 city: ROMA postcode: 161 website: http://www.iss.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	356˙250.00
6	UNIVERSITA DEGLI STUDI DI TRIESTE UNIVERSITA DEGLI STUDI DI TRIESTE Organization address address: PIAZZALE EUROPA 1 city: TRIESTE postcode: 34127 website: www.units.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (TRIESTE)	participant	350˙000.00
7	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	participant	332˙712.00
8	VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA Organization address address: KIINAMYLLYNKATU 4-8 city: TURKU postcode: 20520 website: www.tykd.fin/en contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (TURKU)	participant	297˙312.00
9	AB ANALITICA SRL AB ANALITICA SRL Organization address address: VIA SVIZZERA 16 city: PADOVA postcode: 35127 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PADOVA)	participant	287˙500.00

Map

Project objective

The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient.

This project takes an advantage on prospectively and longitudinally collected fresh sample specimens from multiple anatomic sites of HGS-OvCa patients with metastatic disease. Fluorescence activated cell sorting and recently developed mass cytometry are used to identify subpopulations in HGS-OvCa tumors. This is followed by single-cell analysis at genetic and transcriptomics levels, and ex vivo drug screening experiments. These data will be used to establish network models to predict the most effective combinatorial treatments. The key results will be validated with existing HGS-OvCa data together with prospective and retrospective cohorts and in vivo models. The clinically most actionable treatment suggestions from our modelling efforts will be translated to HGS-OvCa patient care.

Ovarian cancer kills more than 40,000 women in Europe every year due to lack of effective and long-lasting therapeutic regimens. HERCULES presents an innovative strategy to suggest effective treatments that lead to a marked decrease in ovarian cancer deaths and reduce the number of expensive but inefficient treatments. Our approach paves the way to move beyond the current trial-and-error clinical assessment of drug combinations toward more systematic prediction of the most effective drug combinations for each patient. The proposed approach will be a major breakthrough in systems medicine and will benefit individual ovarian cancer patients and the health-care system through more effective treatments, and the diagnostic and pharmaceutical industry through tools for better stratified clinical trials, and novel treatment and diagnostic modalities.

Deliverables

List of deliverables.
Evaluation of flow cytometry and imaging-based clonal drug response assays	Demonstrators, pilots, prototypes	2019-05-28 17:19:33
One or more software components that automate import and integration of modelling data into Cytoscape	Other	2019-05-24 19:13:12
Project presentation produced	Documents, reports	2019-05-24 16:49:29
Knowledge Management System up and running	Websites, patent fillings, videos etc.	2019-05-24 16:49:28
Project Office with Operational Project Manager in place and Project Management Committee	Websites, patent fillings, videos etc.	2019-05-24 16:49:28
A workflow for obtaining consents from advanced HGS-OvCa patients, and for collecting samples from the patients	Documents, reports	2019-05-24 16:49:29
Data Management Plan	Open Research Data Pilot	2019-05-24 16:49:28

Take a look to the deliverables list in detail: detailed list of HERCULES deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Emilia KozÅ‚owska, Anniina FÃ¤rkkilÃ¤, Tuulia Vallius, Olli CarpÃ©n, Jukka Kemppainen, Seija GrÃ©nman, Rainer Lehtonen, Johanna Hynninen, Sakari Hietanen, Sampsa Hautaniemi Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer published pages: 4036-4044, ISSN: 0008-5472, DOI: 10.1158/0008-5472.can-17-3746	Cancer Research 78/14	2019-05-22
2018	J. Hynninen, M. Laasik, T. Vallius, J. Kemppainen, S. GrÃ¶nroos, J. Virtanen, J. Casado, S. Hautaniemi, S. Grenman, M. SeppÃ¤nen, A. Auranen Clinical Value of 18 F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer published pages: 507-514, ISSN: 0936-6555, DOI: 10.1016/j.clon.2018.04.007	Clinical Oncology 30/8	2019-05-22
2018	Antti HÃ¤kkinen, Amjad Alkodsi, Chiara Facciotto, Kaiyang Zhang, Katja Kaipio, Sirpa LeppÃ¤, Olli CarpÃ©n, Seija GrÃ©nman, Johanna Hynninen, Sakari Hietanen, Rainer Lehtonen, Sampsa Hautaniemi Identifying differentially methylated sites in samples with varying tumor purity published pages: 3078-3085, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/bty310	Bioinformatics 34/18	2019-05-22
2018	Iryna Nikolayeva, Oriol Guitart Pla, Benno Schwikowski Network module identificationâ€”A widespread theoretical bias and best practices published pages: 19-25, ISSN: 1046-2023, DOI: 10.1016/j.ymeth.2017.08.008	Methods 132	2019-05-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HERCULES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HERCULES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More